Novartis to spend $1.1 billion upfront acquiring Myricx Bio and its next-gen ADC platform
read at Endpoints ↗DealPositive
Novartis announced Monday it will invest $1.1 billion in an upfront payment to acquire Myricx Bio.
Myricx Bio brings an antibody-drug conjugate (ADC) payload platform that the Swiss group believes could provide a competitive edge over existing technologies.
The deal gives Novartis access to Myricx’s next-generation ADC capabilities as it expands its oncology pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform”
read at Endpoints ↗88 words · retrieved Jul 6
comments(0)
5-min edit window · permanent after that